Literature DB >> 16707592

RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells.

Hideaki Tsutsumida1, Benjamin J Swanson, Pankaj K Singh, Thomas C Caffrey, Shinichi Kitajima, Masamichi Goto, Suguru Yonezawa, Michael A Hollingsworth.   

Abstract

MUC1 is a highly glycosylated, type I transmembrane protein expressed by normal ductal epithelial cells of the pancreas, breast, lung, and gastrointestinal tract, and overexpressed in many cases of adenocarcinoma. We down-regulated MUC1 expression by RNA interference and investigated the effects on malignant and metastatic potential of a human pancreatic cancer cell line, S2-013. MUC1-suppressed clones, S2-013.MTII.C1 and S2-013.MTII.C2, were established by targeting a sequence 3,151 bp from the initiation codon and characterized in vitro for proliferation, invasion, and adhesion. We evaluated the effects of MUC1 suppression in vivo on tumor growth and metastatic properties following implantation into the cecum or pancreas of athymic mice. MUC1-suppressed clones showed significantly decreased proliferation in vitro and in vivo. Global gene expression was evaluated by oligonucleotide microarray analysis. Surprisingly, genes predicted to increase doubling times (cyclin B1 and cyclin D3) were overexpressed in MUC1-suppressed clones. There were alterations in expression of several genes that may affect the malignant properties of pancreatic cancer. Adhesion of MUC1-suppressed cells in vitro to type IV collagen and fibronectin was slightly increased, and adhesion was slightly decreased to type I collagen and laminin. Results of implantation to cecum and pancreas showed significant reduction of metastasis to lymph nodes, lung, or peritoneal sites compared with S2-013.gfp-neo control cells. These results support the hypothesis that MUC1 contributes significantly to growth and metastasis, and that down-regulation of MUC1 protein expression decreases the metastatic potential of pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707592     DOI: 10.1158/1078-0432.CCR-05-1197

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  55 in total

1.  O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.

Authors:  Pushpa Premaratne; Karin Welén; Jan-Erik Damber; Gunnar C Hansson; Malin Bäckström
Journal:  Tumour Biol       Date:  2010-09-26

Review 2.  Genetically engineered mucin mouse models for inflammation and cancer.

Authors:  Suhasini Joshi; Sushil Kumar; Sangeeta Bafna; Satyanarayana Rachagani; Kay-Uwe Wagner; Maneesh Jain; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 3.  Mucin-based targeted pancreatic cancer therapy.

Authors:  Maria P Torres; Subhankar Chakraborty; Joshua Souchek; Surinder K Batra
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

Review 5.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Amyloid precursor-like protein 2 association with HLA class I molecules.

Authors:  Amit Tuli; Mahak Sharma; Xiaojian Wang; Laura C Simone; Haley L Capek; Steven Cate; William H Hildebrand; Naava Naslavsky; Steve Caplan; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2009-01-31       Impact factor: 6.968

7.  Sonic hedgehog promotes desmoplasia in pancreatic cancer.

Authors:  Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

8.  Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.

Authors:  Xuede Lin; Xiaojian Wang; Haley L Capek; Laura C Simone; Amit Tuli; Chantey R Morris; Adrian J Reber; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2008-10-01       Impact factor: 6.968

9.  RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells.

Authors:  Sadaaki Yamazoe; Hiroaki Tanaka; Tetsuji Sawada; Ryosuke Amano; Nobuya Yamada; Masaichi Ohira; Kosei Hirakawa
Journal:  J Exp Clin Cancer Res       Date:  2010-05-23

10.  Gene expression profiles associated with advanced pancreatic cancer.

Authors:  Domenico Campagna; Leslie Cope; Sindhu S Lakkur; Clark Henderson; Daniel Laheru; Christine A Iacobuzio-Donahue
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.